These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37552656)

  • 1. N-dihydrogalactochitosan reduces mortality in a lethal mouse model of SARS-CoV-2.
    Weiss CM; Liu H; Ball EE; Hoover AR; Wong TS; Wong CF; Lam S; Hode T; Keel MK; Levenson RM; Chen WR; Coffey LL
    PLoS One; 2023; 18(8):e0289139. PubMed ID: 37552656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Nasal and Lung Tissues Infected
    Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG
    J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition.
    Pan R; Kindler E; Cao L; Zhou Y; Zhang Z; Liu Q; Ebert N; Züst R; Sun Y; Gorbalenya AE; Perlman S; Thiel V; Chen Y; Guo D
    mBio; 2022 Feb; 13(1):e0366221. PubMed ID: 35073761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
    Dinnon KH; Leist SR; Schäfer A; Edwards CE; Martinez DR; Montgomery SA; West A; Yount BL; Hou YJ; Adams LE; Gully KL; Brown AJ; Huang E; Bryant MD; Choong IC; Glenn JS; Gralinski LE; Sheahan TP; Baric RS
    Nature; 2020 Oct; 586(7830):560-566. PubMed ID: 32854108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
    Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
    Front Immunol; 2022; 13():858904. PubMed ID: 35592324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection.
    Hassler L; Wysocki J; Gelarden I; Sharma I; Tomatsidou A; Ye M; Gula H; Nicoleascu V; Randall G; Pshenychnyi S; Khurram N; Kanwar Y; Missiakas D; Henkin J; Yeldandi A; Batlle D
    J Am Soc Nephrol; 2022 Jul; 33(7):1293-1307. PubMed ID: 35236774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
    Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
    J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal Models of COVID-19: Transgenic Mouse Model.
    Park JG; Pino PA; Akhter A; Alvarez X; Torrelles JB; Martinez-Sobrido L
    Methods Mol Biol; 2022; 2452():259-289. PubMed ID: 35554912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice.
    Thieulent CJ; Dittmar W; Balasuriya UBR; Crossland NA; Wen X; Richt JA; Carossino M
    mSphere; 2023 Feb; 8(1):e0055822. PubMed ID: 36728430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
    Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
    J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2.
    Golden JW; Li R; Cline CR; Zeng X; Mucker EM; Fuentes-Lao AJ; Spik KW; Williams JA; Twenhafel N; Davis N; Moore JL; Stevens S; Blue E; Garrison AR; Larson DD; Stewart R; Kunzler M; Liu Y; Wang Z; Hooper JW
    mBio; 2022 Feb; 13(1):e0290621. PubMed ID: 35073750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
    Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
    Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
    mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR2 Signaling Restricts SARS-CoV-2 Infection.
    Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
    mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.